TUSTIN, Calif., Dec. 8, 2011 /PRNewswire/ — Radient
Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC),
developer and marketer of the Onko-Sure® In Vitro
Diagnostic (IVD) cancer test, announced today that it has
submitted one abstract for the American Society of Colon and Rectal
Surgeons’ (ASCRS) Annual Meeting to be held in June 2012.
ASCRS is the premier society for colon and rectal surgeons and
other surgeons dedicated to advancing and promoting the science and
practice of the treatment of patients with disease and disorders
affecting the colon, rectum and anus.
The title of the abstract submitted is “Combined DR-70 and CEA
testing is advantageous over CEA alone in the detection of
colorectal cancer and specially the right-sided type.” More than
1,000 of the Society’s members are certified by the American Board
of Colon and Rectal Surgery. The meeting will be held from June 2nd
to 6th, 2012 in San Antonio, TX. Over 1,200 surgeons are expected
to attend.
If accepted, Robert Beart Jr., M.D., who was appointed to the
Company’s Board of Directors in June 2010, will make the Company
presentation. Dr. Beart currently is the medical director of
the Glendale Hospital CRC Institute. Previously he was with
the University of Southern California since 1992, establishing the
Division of Colorectal Surgery in the USC Department of Surgery as
well as launching the USC Center for Colorectal Diseases at USC
University Hospital and USC/Norris Cancer Center and
Hospital.
Dr. Beart is a recognized specialist and expert in colorectal
diseases and cancer, pioneer of the ileal pouch-anal anastomosis,
and thought leader in the medical, scientific and research
communities. Dr. Beart’s primary experience and
research includes the identification and management of recurrent
colorectal cancer. He has broad and deep clinical involvement
in colorectal diseases, covering key areas that include
colorect
‘/>”/>
